Searching for the hereditary causes of renal-cell carcinoma

Nature Reviews Cancer

Volumn 4, Issue 5, 2004, Pages 381-393

  Pavlovich, Christian P ^a   Schmidt, Laura S ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; SCATTER FACTOR RECEPTOR; VON HIPPEL LINDAU PROTEIN;

BIOCHEMISTRY; BIRT HOGG DUBE SYNDROME; CARCINOGENESIS; FAMILIAL CANCER; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PREDISPOSITION; HEREDITY; HUMAN; HYPERPARATHYROIDISM JAW TUMOR SYNDROME; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 2342583527     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1364     Document Type: Review

References (169)

1. Zbar, B., Klausner, R. & Linehan, W. M. Studying cancer families to identify kidney cancer genes. Annu. Rev. Med. 54, 217-233 (2003).
2. Chow, W. H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
3. Kovacs, G. et al. The Heidelberg classification of renal cell tumours. J. Pathol, 183, 131-133 (1997).
4. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993). Describes the identification and cloning of the VHL tumour-suppressor gene and intragenic mutations in members of families with VHL.
5. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68-73 (1997). First report of activating mutations in the MET protooncogene in inherited human cancer and identification of the causative gene for HPRC.
6. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet. 30, 406-410 (2002). Identification of germline inactivating mutations in FH that predispose to HLRCC with papillary type-2 renal carcinoma.
7. Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2, 157-164 (2002). Identification of germline protein-truncating mutations in a novel gene, BHD, in families with BHD syndrome leading to renal neoplasia of various histologies.
8. Carpten, J. D. et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genet. 32, 676-680 (2002). First report of germline inactivating mutations in a novel tumour-suppressor gene, HRPT2, in families with HPT-JT syndrome and associated renal neoplasia.
9. Cohen, A. J. et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301, 592-595 (1979). First report of a family with a belanced translocation involving chromosome 3 and a predisposition to renal-cell carcinoma.
10. Kovacs, G., Brusa, P. & De Riese, W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int. J. Cancer 43, 422-427 (1989).
11. Bodmer, D. et al. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am. J. Hum. Genet. 62, 1475-1483 (1998).
12. Malchoff, C. D. et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1758-1764 (2000).
13. Lendvay, T. S. & Marshall, F. F. The tuberous sclerosis complex and its highly variable manifestations. J. Urol. 169, 1635-1642 (2003).
14. Krymskaya, V. P. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 15, 729-739 (2003).
15. Dome, J. S. & Coppes, M. J. Recent advances in Wilms' tumor genetics. Curr. Opin. Pediatr. 14, 5-11 (2002).
16. Maher, E. R. & Kaelin, W. G. Jr. von Hippel-Lindau disease. Medicine 76, 381-391 (1997).
17. Chen, F. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66-75 (1995).
18. Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348-357 (1996).
19. Crossey, P. A. et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum. Genet. 93, 53-58 (1994).
20. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994).
21. Vortmeyer, A. O. et al. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 21, 1167-1170 (2002).
22. Lubensky, I. A. et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol. 149, 2089-2094 (1996).
23. Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-68 (2002).
24. Foster, K. et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169-2173 (1994).
25. Gnarra, J. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85-90 (1994). First demonstration of VHL mutation and LOH in most of sporadic clear-cell renal-cell carcinomas, which is the most common form of renal cancer.
26. Shuin, T. et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852-2855 (1994).
27. Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome, Nature Rev. Cancer 2, 673-682 (2002).
28. Kaelin, W. G. Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14, 2703-2711 (2003).
29. Maxwell, P. HIF-1: an oxygen response system with special relevance to the kidney. J. Am. Soc. Nephrol. 14, 2712-2722 (2003).
30. Kim, W. & Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13, 55-60 (2003).
31. Pugh, C. W. & Ratcliffe, P. J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 13, 83-89 (2003).
32. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999). Landmark publication that demonstrated an interaction between VHL and HIF proteins, and stability of HIF-α subunits in VHL-deficient cell lines.
33. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578 (1999).
34. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
35. Stebbins, C. E., Kaelin, W. G. Jr., & Pavletich, N. P. Structure of the VHL-Elongin C-Elongin B complex: implications for VHL tumor suppressor function. Science 284, 455-461 (1999). Crystal structure of VHL protein in complex with elongins B and C that identified the frequently mutated α- and β-domains.
36. Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156-2161 (1997).
37. Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 417, 975-978 (2002).
38. Min, J. H. et al. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
39. 2 sensing. Science 292, 464-468 (2001). This paper and reference 40 demonstrated that the VHL-HIF interaction is regulated by oxygen-dependent prolyl hydroxylation.
40. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
41. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
42. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
43. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. & Whitelaw, M. L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295, 858-861 (2002).
44. Mahon, P. C., Hirota, K. & Semenza, G. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001).
45. -/- renal carcinoma cells suppressed the formation of tumours in nude mice.
46. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002). The creation of a stable HIF mutant prevents tumour suppression by VHL in a nude mouse model, implicating the VHL-HIF interaction as critical to the growth of renal cancer cells.
47. Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G., Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLOS Biol. 1, 439-444 (2003).
48. Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002). VHL substrate binding at the HIF recognition domain of VHL protein was shown to be essential to the tumour-suppressor function of VHL, but artificially increasing HIF levels alone was not sufficient for tumorigenesis.
49. Gnarra, J. R. et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 93, 10589-10594 (1996).
50. Levy, A. P., Levy, N. S., & Goldberg, M. A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271, 25492-25497 (1996).
51. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595-10599 (1996).
52. Siemeister, G. et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299-2301 (1996).
53. Knebelmann, B., Ananth, S., Cohen, H. T. & Sukhatme, V. P. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58, 226-231 (1998).
54. -/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl Acad. Sci. USA 98, 1387-1392 (2001).
55. Ohh, M. et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959-968 (1998).
56. Chen, F. et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 55, 4804-4807 (1995).
57. Pause, A., Lee, S., Lonergan, K. M., & Klausner, R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl Acad. Sci. USA 95, 993-998 (1998).
58. Davidowitz, E. J., Schoenfeld, A. R. & Burk, R. D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 21, 865-874 (2001).
59. Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M. & Klausner, R. D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014-3019 (2002).
60. Baba, M. et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22, 2728-2738 (2003).
61. Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311 (2003).
62. Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat., 8, 348-357 (1996).
63. Friedrich, C. A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 10, 763-767 (2001).
64. Clifford, S. C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet, 10, 1029-1038 (2001).
65. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biol. 5, 64-70 (2003).
66. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Gen. 10, 1019-1027 (2001).
67. Feldman, D. E., Spiess, C., Howard, D. E. & Frydman, J. Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol. Cell 12, 1213-1224 (2003).
68. Maranchie, J. K. et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum. Mutat. 23, 40-46 (2004).
69. Gnarra, J. R. et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl Acad. Sci. USA 94, 9102-9107 (1997).
70. Haase, V. H., Glickman, J. N., Socolovsky, M. & Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl Acad. Sci. USA 98, 1583-1588 (2001).
71. Ma, W. et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 63, 5320-5328 (2003).
72. Zbar, B. et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J. Urol. 153, 907-912 (1995).
73. Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 58, 1719-1722 (1998).
74. Schmidt, L. et al. Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 18, 2343-2350 (1999).
75. Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int. J. Cancer 82, 640-643 (1999).
76. Bottarro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991). A molecule upregulated after treatment of target cells in vitro with HGF was found to be identical to the c-MET proto-oncogene product, now known as the HGF transmembrane tyrosine kinase receptor.
77. Bardelli, A., Pugliese, L., & Comoglio, P. M. 'Invasive growth' signalling by the Met/HGF receptor. The hereditary renal carcinoma connection. Biochim. Biophys. Acta. 1333, M41-M51 (1997).
78. Comoglio, P. M. Pathway specificity for Met signaling. Nature Cell Biol. 3, E161-E162 (2001).
79. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4, 915-925 (2003).
80. Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289-300 (2002).
81. Jeffers, M. et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl Acad. Sci. USA 94, 11445-11450 (1997).
82. Hofstra, R. M. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375-376 (1994).
83. Nagata, H. et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci. USA 92, 10560-10564 (1995).
84. Shu, H. K., Pelley, R. J. & Kung, H. J. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc. Natl Acad. Sci. USA 87, 9103-9107 (1990).
85. Miller, M. et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44, 32-43 (2001).
86. Michieli, P. et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18, 5221-5231 (1999).
87. Chiara, F., Michieli, P., Pugliese, L. & Comoglio, P. M. Mutations in the met oncogene unveil a 'dual switch' mechanism controlling tyrosine kinase activity. J. Biol. Chem. 278, 29352-29358 (2003).
88. Zhuang, Z. et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genet. 20, 66-69 (1998).
89. Fischer, J. et al. Duplication end overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17, 733-739 (1998).
90. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702 (1995).
91. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705 (1995).
92. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995).
93. Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA 95, 14417-14422 (1998).
94. Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Invest. 97, 2872-2877 (1996).
95. Launonen, V. et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98, 3387-3392 (2001).
96. Kiuru, M. et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am. J. Pathol. 159, 825-829 (2001).
97. Delahunt, B. et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol. 32, 590-595 (2001).
98. Jiang, F. et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol. 153, 1467-1473 (1998).
99. Toro, J. et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95-106 (2003).
100. Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12, 1241-1252 (2003).
101. Alam, N. A. et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am. J. Hum. Genet. 68, 1264-1269 (2001).
102. Kiuru, M. et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62, 4554-4557 (2002).
103. Bevan, S. et al. Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. Prostate Cancer Prostatic Dis. 6, 12-14 (2003).
104. Barker, K. T. et al. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br. J. Cancer 87, 446-448 (2002).
105. Coughlin, E. M. et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol. Genet. Metab. 63, 254-262 (1998).
106. Eng, C., Kiuru, M., Fernandez, M. J. & Aaltonen, L. A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Rev. Cancer 3, 193-202 (2003).
107. Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153-159 (2004).
108. Birt, A. R., Hogg, G. R. & Dubé, W. J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 113, 1674-1677 (1977).
109. Weirich, G. et al. Familial renal oncocytoma: clinicopathological study of 5 families. J. Urol. 160, 335-340 (1998).
110. Toro, J. et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch. Dermatol. 135, 1195-1202 (1999).
111. Zbar, B. et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol. Biomarkers Prev. 11, 393-400 (2002). An attempt to define BHD as a cancer-predisposition syndrome from its humble origins as a 'simple' genodermatosis.
112. Khoo, S. K. et al. Clinical and genetic studies of Birt-Hogg-Dubé syndrome. J. Med. Genet. 39, 906-912 (2002).
113. Pavlovich C. P. et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am. J. Surg. Pathol. 26, 1542-1552 (2002).
114. Tickoo, S. K. et al. Renal oncocytosis: a morphologic study of fourteen cases. Am. J. Surg. Pathol. 23, 1094-1101 (1999).
115. Schmidt, L. S. et al. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am. J. Hum. Genet. 69, 876-882 (2001).
116. Khoo, S. K. et al. Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 20, 5239-5242 (2001).
117. Streisinger, G. et al. Frameshift mutations and the genetic code. Cold Spring Harbor Symp. Quant. Biol. 31, 77-86 (1966).
118. Okimoto, K. et al. A novel 'Nihon' rat model of a Mendelian dominantly inherited renal cell carcinoma. Jpn J. Cancer Res. 91, 1096-1099 (2000). A spontaneous and now established rat model of renal cancer similar to human BHD that may be a valuable research tool. Also sea references 119 and 120.
119. Hino, O., Okimoto, K., Kouchi, M. & Sakurai, J. A novel renal carcinoma predisposing gene of the Nihon rat maps on chromosome 10. Jpn J. Cancer Res. 92, 1147-1149 (2001).
120. Okimoto, K. et al. A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc. Natl Acad. Sci. USA 101, 2023-2027 (2004).
121. Lium, B. & Moe, L. Hereditary multifocal renal cystadenocarcinomas and nodular dermatofibrosis in the German shepherd dog: macroscopic and histopathologic changes. Vet. Pathol. 22, 447-455 (1985).
122. Jonasdottir, T. J. et al. Genetic mapping of a naturally occurring hereditary renal cancer syndrome in dogs. Proc. Natl Acad. Sci. USA 97, 4132-4137 (2000).
123. Lingaas, F. et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum. Mol. Genet. 12, 3043-3053 (2003). The first natural large animal model for renal-cell carcinoma.
124. Khoo, S. K. et al. Inactivation of BHD in sporadic renal tumors. Cancer Res. 63, 4583-4587 (2003).
125. da Silva, N. F. et al. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J. Med. Genet. 40, 820-824 (2003).
126. Pavlovich, C. P. et al. Genetic analysis of renal cell carcinomas in Birt-Hogg-Dubé (BHD) syndrome. Proc. Am. Assoc. Cancer Res. 43, 632 (2002).
127. Shin, J. H. et al. Mutations of the Birt-Hogg-Dubé (BHD) gene in sporadic colorectal carcinomas and colorectal carcinoma cell lines with microsatellite instability. J. Med. Genet. 40, 364-367 (2003).
128. Kahnoski, K. et al. Alterations of the Birt-Hogg-Dubé gene (BHD) in sporadic colorectal tumours. J. Med. Genet, 40, 511-515 (2003).
129. Jackson, C. E. et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108, 1006-1012 (1990).
130. Szabo, J. et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am. J. Hum. Genet. 56, 944-950 (1995).
131. Teh, B. T. et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol. Metab. 81, 4204-4211 (1996).
132. Haven, C. J. et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol. Metab. 65, 1449-1454 (2000).
133. Shattuck, T. M. et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722-1729 (2003).
134. Howell, V. M. et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. 40, 657-663 (2003).
135. Bodmer, D. et al. Understanding familial and non-familial renal cell cancer. Human Mol. Genet. 11, 2489-2498 (2002).
136. Ohta, M. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587-597 (1996).
137. Ong, S. T. et al. Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosom. Cancer 20, 16-23 (1997).
138. Siprashvili, Z. et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl Acad. Sci. USA 94, 13771-13776 (1997).
139. Gemmill, R. M. et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc. Natl Acad. Sci. USA 95, 9572-9577 (1998).
140. Gemmill, R. M. et al. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 21, 3507-3516 (2002).
141. Druck, T. et al. The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J. Hum. Genet. 46, 583-589 (2001).
142. Bodmer, D. et al. Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum. Mol. Genet. 11, 641-649 (2002).
143. Bodmer, D., Schepens, M., Eleveld, M. J., Schoenmakers, E. F. & Geurts van Kessel, A. Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2;3)(q35;q21). Genes Chromosom. Cancer 36, 107-116 (2003).
144. Chen, J. et al. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 4, 405-413 (2003).
145. Schmidt, L. et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J. Sci. Am. 1, 191-194 (1995).
146. Woodward, E. R., Clifford, S. C., Astuti, D., Affara, N. A. & Maher, E. R. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J. Med. Genet. 37, 348-353 (2000).
147. Teh, B. et al. Familial non-VHL non-papillary clear cell renal cancer. Lancet 349, 848-849 (1997).
148. Gudbjartsson, T. et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int. J. Cancer 100, 476-479 (2002). Shows that the future of gene discovery for RCC could rely on the discovery of predispositions that are more subtle than those found so far, which have been autosomal dominant syndromes following classic Mendelian inheritance.
149. Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. & Yu, M. C. Family history and risk of renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 10, 1001-1004 (2001).
150. Choyke, P. L. Imaging of hereditary renal cancer. Radiol. Clin. North Am. 41, 1037-1051 (2003).
151. Lonser, R. R. et al. von Hippel-Lindau disease. Lancet 361, 2059-2067 (2003).
152. Stolle, C. et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417-423 (1998).
153. Herring, J. C. et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J. Urol. 165, 777-781 (2001). Along with reference 156, a demonstration that nephron-sparing approaches are appropriate for patients with syndromes placing them at continued risk of renal neoplasia.
154. Pavlovich, C. P. et al. Percutaneous radiofrequency ablation of small renal tumors: initial results. J. Urol. 167, 10-15 (2002).
155. Shingleton, W. B. & Sewell, P. E. Jr. Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease. J. Urol. 167, 1268-1270 (2002).
156. Steinbach, F. et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J. Urol. 153, 1812-1816 (1995).
157. Grady, W. M. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101-128 (2002).
158. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
159. Koochekpour, S. et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell Biol. 19, 5902-5912 (1999).
160. Amato, R. J. Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol. Hematol. 46, S59-S65 (2003).
161. Lara, P. N. Jr et al. SU5416 plus interferon α in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. 9, 4772-4781 (2003).
162. Yang, J. C. et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
163. Sattler, M. et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63, 5462-5469 (2003).
164. Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342-349 (2000).
165. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
166. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
167. Higgins, J. P. et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am. J. Pathol. 162, 925-932 (2003).
168. Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754-9759 (2001).
169. Vasselli, J. R. et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc. Natl Acad. Sci. USA 100, 6958-6963 (2003).